iRhythm Holdings completed its acquisition of VitalConnect on Oct. 5, 2026, paying $237.5 million in cash, subject to customary adjustments, and issuing up to 423,334 shares at closing. The company also provided $10.0 million of working capital funding to VitalConnect between signing and closing.
The deal expands iRhythm’s cardiac monitoring platform across ambulatory, inpatient and hospital-to-home care. VitalConnect adds mobile cardiac telemetry capabilities, up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in. Its platform can monitor up to 11 physiological parameters, extending iRhythm’s multi-vitals strategy beyond traditional ambulatory cardiac monitoring.
iRhythm said the acquisition immediately broadens its capabilities in ambulatory cardiac monitoring, including MCT, and expands its addressable market across the continuum of care. The company said the combination should accelerate commercial growth by leveraging its scale, customer relationships and go-to-market capabilities.
The transaction is expected to improve iRhythm’s revenue growth rate beginning in 2027 while preserving its previously stated 15% adjusted EBITDA margin target for 2027.
iRhythm said it will provide updated 2026 financial guidance, including VitalConnect, during its third-quarter earnings call on Nov. 5, 2026. As a result of these announcements, the company's shares have moved -0.61% on the market, and are now trading at a price of $110.37. For the full picture, make sure to review iRhythm's 8-K report.
